PDF: 2.11.2012 WBB Securities’ Stephen Brozak to Moderate Panel at 2012 BIO CEO and Investor Conference
WBB Securities’ Stephen Brozak to Moderate Panel at 2012 BIO CEO and Investor Conference
Mr. Brozak to be joined by distinguished panel of venture investors and leading diagnostic companies
For Immediate Release
February 11, 2012
SAN DIEGO, CA– WBB Securities Managing Partner and President, Stephen G. Brozak, will be moderating the Diagnostics workshop at the 2012 BIO CEO and Investor Conference. Mr. Brozak’s workshop will begin on February 14, 2012, at 10:30 am at the Waldorf-Astoria Hotel in New York, NY.
About WBB Securities
WBB Securities is a leading investment management, investment banking, and equity research firm. Established in 2001 and headquartered in San Diego, California, WBB Securities is a registered independent broker dealer and investment advisor with proprietary trading desks that have market-making capabilities. WBB Securities has built a nationwide team of respected senior investment and research professionals with a network of branches throughout the US serving institutional and high net worth clients. The firm also maintains an investment banking and equity research practice focused exclusively in the life sciences niche. www.wbbsec.com
About BIO CEO & Investor Conference
Now in its fourteenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on publicly traded biotechnology companies.
Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.
The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.
The therapeutic workshops feature MDs, CSOs and industry analysts discussing the latest information on pipeline innovation for breakthrough therapeutic topics in biopharma. Seasoned industry executives and analysts delve into timely and relevant business models, dealmaking and investment trends on our business roundtables.
